Printed from Voxsanity (voxsanity.com.au) — NCT06992427 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Head And Neck Cancer
Phase 3 Head and Neck Cancer Trial, Recruiting
NCT06992427
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with squamous cell carcinoma (a specific type of cancer) in the head and neck area, at any stage from I to IV
- People who have not had any previous treatment for head and neck cancer
- People whose doctors have planned treatment using a chemotherapy drug called cisplatin combined with radiation therapy
- People who are able to swallow capsules whole
- People who are 18 years of age or older
- People whose general health and ability to carry out daily activities meets a standard level (confirm with trial site)
- People whose kidney function blood test results are within an acceptable range (confirm with trial site)
- Women who are not pregnant and not breastfeeding; women who could become pregnant must have a negative pregnancy test done within 7 days before joining the study, and must agree to use contraception during treatment and for 6 months after finishing chemoradiation
- People who are able to speak and read English or Spanish
- People who are able to make their own informed decisions about joining the study
- People who have a history of thyroid cancer treated with surgery and radioactive iodine may still be considered eligible (confirm with trial site)
Who may not be able to join:
- People who have previously had surgery or radiation treatment for head and neck cancer, or who are being treated for head and neck cancer that has come back
- People who have a known allergy or sensitivity to gabapentin or any of its ingredients
- People currently on kidney dialysis or who have received a transplanted organ
- People who have additional surgery, chemotherapy, or immunotherapy planned after the 7-week chemoradiation treatment
- People who have cancer that has spread to the brain
- People who have used non-prescribed opioid drugs (including heroin) within the 6 months before joining the study
- People who are currently taking prescribed medications for ongoing or long-term pain or nerve-related conditions, or who are under the care of a pain specialist or substance abuse program (short-term pain medication taken after a biopsy may be acceptable if stopped at least 3 days before joining — confirm with trial site)
- People currently taking the medication mefloquine
- People currently taking medications for a psychotic psychiatric illness
- People who have already been diagnosed with sleep apnea
- People who have a condition called acute narrow-angle glaucoma
- People with serious uncontrolled health conditions, such as an active infection, heart failure, unstable chest pain, irregular heartbeat, or psychiatric or personal circumstances that would make it difficult to follow the study requirements
- People who have received any experimental treatment or drug within 30 days before joining the study
- People who are currently enrolled in another study involving medications for pain control
- People currently receiving treatment for other cancers at the same time
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Phone: 773-702-9171
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
5 June 2025
Est. completion
15 August 2029
Where this trial is recruiting
🇺🇸 United States
Primary endpoints
Need to use opioids during chemoradiation therapy (CRT)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.